• 1
    MacMahon SW, Cutler JA, Furberg CD, et al. The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized clinical trials. Prog Cardiovasc Dis. 1986;29(suppl 1):99118.
  • 2
    Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:12811285.
  • 3
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 4
    Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97104.
  • 5
    Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension. 1985:7:457468.
  • 6
    Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995;7(3):242250.
  • 7
    Fletcher A. Cost effective analyses in the treatment of high blood pressure. J Hum Hypertens. 1992;6:437445.
  • 8
    Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens. 1991;9:199208.
  • 9
    Jonsson BG. Cost-benefit of treating hypertension. J Hypertens. 1994;12(suppl 10):S65S70.
  • 10
    Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157(21):24132446.
  • 11
    Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305313.
  • 12
    Bloom BS. Daily regimen and compliance with treatment. BMJ. 2001;323:647.
  • 13
    Mancia G, Sega R, Milesi C, et al. Blood pressure control in the hypertensive population. Lancet. 1997;349:454457.
  • 14
    Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis on persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther. 2002;24(8):13471357.
  • 15
    Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16:439444.
  • 16
    Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20(4):671681.
  • 17
    Caro JJ, Salas M, Speakman JL, et al. Persistence with treatment for hypertension in actual practice. Can Med Assoc J. 1999;160:3137.
  • 18
    Flack JM, Novikov SV, Ferrario CM. Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. 1996;17(suppl A):1620.
  • 19
    Meredith PA. Therapeutic implication of drug “holidays.” Eur Heart J. 1996;17(suppl A):2124.
  • 20
    Stason WB. Compliance, quality of life, and cost effectiveness. Curr Hypertens Rep. 1999;1:471474.
  • 21
    Skaer TL, Sclar DA, Robison LM. Noncompliance with antihypertensive therapy. Economic consequences. Pharmacoeconomics. 1996;9(1):14.
  • 22
    Urquhart J. Some economic consequences of noncompliance. Curr Hypertens Rep. 2001;3:473480.
  • 23
    Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996;17(suppl A):815.
  • 24
    Degli Esposti E, Sturani A, Degli Esposti L, et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther. 2001;39:251258.
  • 25
    Degli Esposti L, Baio G, Valpiani G. Cost allocation in antihypertensive drug therapies. Exp Rev Pharmacoeconomics Outcomes Res. 2002;2(5):419426.
  • 26
    Scardovi I, Monari P. Metodologia Statistica in Biologia e Medicina. Torino , Italy : Unione Tipografico-Editrice Torinese (UTET); 1993.
  • 27
    Marubini E, Valsecchi MG, Emmerson M. Analysing Survival Data from Clinical Trials and Observational Studies. New York , NY : Wiley; 1995.
  • 28
    Jones JK, Gorkun L, Lian JR, et al. Discontinuation of and changes in the treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ. 1995;311:293295.
  • 29
    Curb JD, Borhani NO, Blaszkowski TP, et al. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253:32633268.
  • 30
    Haines RB. A critical review of the “determinants” of patient compliance with therapeutic regimens. In: SackettDL, HaynesRB, eds. Compliance With Therapeutic Regimens. Baltimore , MD : The Johns Hopkins University Press; 1976:2639.
  • 31
    Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995;130:572579.
  • 32
    Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther. 1996;18:608625.
  • 33
    Goldberg AI, Dunlay MC, Sweet CS, et al. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared to hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793795.
  • 34
    Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens. 1995;8:578583.